Archives

SIRIO Pharma receives Sports Nutrition Production License approval, potentially opening up sizable sports product growth in China

Shanghai, February 19, 2019: Sirio Pharma Co. Ltd (SIRIO) – the global nutraceutical contract development and manufacturing organization (CDMO) – today announces that it has been granted SC (production license) of sports nutrition food in China.

The approval enables Sirio to add special sports nutrition ingredients into products and covers six functional classes for ‘protein supplementary’, ‘speed & power’, ‘endurance’, ‘energy control’, ‘energy supplementary’, and ‘post-exercise recovery’. Due to the stringency of regulations and complexity of achieving approval, Sirio is now one of just seven approved license holders in the country.

“In the last few years, sports nutrition in China has grown extremely quickly – at a CAGR of 37% between 2013-2017 – and is forecast to continue to expand at up to 50% per year, easily outstripping growth in the USA and other global markets. So it is a huge opportunity not only for domestic companies, but also international brands” commented Rui Yang, CSO of SIRIO Pharma.

Until recently, the barriers to entry for international brands in China were high, and the majority entered the market using cross-border e-commerce. However, Sirio’s new sports license – coupled with its strong formulation capabilities and capacity – now provide the possibility of contract manufacturing these products in China and selling through all distribution channels across the country. Potentially opening-up a far larger customer base. It also enables international brands to start developing customized sports nutrition products that are tailored to local consumer preferences in China.

Significantly, the license allows nutra brands to make specific functional claims on sports nutrition product labeling, and will cover popular ingredients including concentrated whey protein, whey protein isolate, soy protein isolate: BCAA, CaHMB, creatine, and many vitamin & minerals.

Yang added, “The consumer demand for sports products in China has exploded in the last few years, in part thanks to the national fitness policy, yet the production and regulatory environment is still maturing. As a result, only a very small number of companies have licenses and, through Sirio, we foresee tremendous opportunities for brand companies to access one of the fastest growing segments of the nutrition industry globally. In fact, we have already had a number of enquiries and we are able to start production immediately. What is more, for established brands who want to build their name in the China, by partnering with Sirio, they are now even able to develop completely unique products tailored to the Chinese sports consumer.”

Corporate Comm India(CCI Newswire)
The Pharma Times News Bureau

Recent Posts

Dr. Agarwals Eye Hospital Supports Nutritional Well-being of Children with Vehicle Donation to Akshaya Patra Foundation in Hubli

Hubli, May 20, 2024: In a significant move to support child nutrition through effective logistical contributions,…

22 hours ago

Gleneagles Hospital Mumbai Introduces Pediatric Bone Marrow Transplant (BMT) Facility

New Delhi, May 17, 2024: In response to the growing need for specialized pediatric care,…

4 days ago

Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT);

Achieves significant advancement in Cancer Treatment to Enhance Quality of Life  As per the National…

5 days ago

Two Complex Robotic Kidney Transplant Surgeries Successfully Performed at Fortis Hospital Bannerghatta Road

-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…

6 days ago

On International Nurses Day, American Oncology Institute (AOI) launches #TheExtraordinaryCareGiver Campaign as Tribute to Oncology Nurses

Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…

7 days ago

SOCC Unveils A New Era In Paediatric Care: Second Opinion Online Consultations For Children

Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…

1 week ago

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 5420